ARCA biopharma, Inc. Stock

$13.95

6.90% yesterday

Nasdaq, Aug 12, 10:00 pm CET

ISIN

US00211Y4070

Symbol

ORKA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

ARCA biopharma, Inc. Stock price

$13.95

-26.58 65.58% 5Y

Nasdaq, Closing price Tue, Aug 12 2025

+0.90 6.90%

ISIN

US00211Y4070

Symbol

ORKA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$488.6m

Enterprise Value

$139.5m

Net debt

positive

Cash

$349.1m

Shares outstanding

37.4m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

negative

P/B

1.3

Dividends

DPS

$19.36

Yield 1Y | 5Y

0.0% | 0.0%

Growth 1Y | 5Y

- | -

Payout 1Y | 3Y

-387.9% | -109.4%

Increased

1 Year

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

$-113.2m | -

EBIT

$-113.2m | $-113.8m

Net Income

$-104.7m | $-83.1m

Free Cash Flow

$-77.4m

Financial Health

Equity Ratio

96.5%

Return on Equity

-21.9%

ROCE

-31.0%

ROIC

Debt/Equity

0.0

EPS

$-2.5

FCF per Share

$-2.1

Short interest

16.3%

Employees

Rev per Employee

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Get Started for Free Today

ARCA biopharma, Inc. Stock Analysis

Unlock Scores for Free

??

15 Analysts have issued a ARCA biopharma, Inc. forecast:

14x Buy

93%

More details on Analyst Estimates Including Price Targets

15 Analysts have issued a ARCA biopharma, Inc. forecast:

Buy

93%

Hold

Analyst Estimates with Stock Price Targets

Financial data from ARCA biopharma, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	18 18	153% 153% -
- Research and Development Expense	95 95	11,924% 11,924% -
EBITDA	-113 -113	1,320% 1,320% -
- Depreciation and Amortization	0.04 0.04	300% 300% -
EBIT (Operating Income) EBIT	-113 -113	1,318% 1,318% -
Net Profit	-105 -105	1,645% 1,645% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

ARCA biopharma, Inc. Stock News

Neutral

GlobeNewsWire

●

one day ago

Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

First patients dosed in the EVERLAST-A Phase 2a trial of ORKA-001, with data expected in 2H 2026 ORKA-001 Phase 1 data and EVERLAST-A design to be presented at EADV in September 2025 ORKA-002 Phase 1 trial ongoing, with data to be presented around YE 2025 MENLO PARK, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology compa...

Neutral

GlobeNewsWire

●

23 days ago

Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September

IND cleared for the EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe psoriasis, with initial data expected 2H 2026

Neutral

GlobeNewsWire

●

about one month ago

Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer

MENLO PARK, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today announced the promotion of Laura Sandler to Chief Operating Officer.

More ARCA biopharma, Inc. News

Company Profile

ARCA biopharma, Inc. is a biopharmaceutical company, which develops genetically targeted therapies for heart failure and other cardiovascular diseases. The company engages in cardiovascular pathophysiology, molecular genetics and clinical development. Its product candidate, Gencaro is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO.

Head office	United States
CEO	Lawrence Klein
Founded	1992
Website	orukatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now